ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2152

Blau Syndrome: features beyond the classic triad and proposal for clinical criteria

Narendra Bagri1, Nawazish Shaikh2, Manisha jana3, Sushain kalsotra4, Krithika Rajkumar2, Madhumita Roy Chowdhury2, Neerja Gupta2, Danveer Bhadu5, Vishal Gupta2 and Rohan Chawla2, 1All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, 2All India Institute of Medical Sciences, Delhi, Delhi, India, 3ALL INDIA INSTITUTE OF MEDICAL SCIENCES, Delhi, 4All India Institute of Medical Sciences, Delhi, India, 5All India Institute of Medical Sciences, New Delhi, New Delhi, Delhi, India

Meeting: ACR Convergence 2025

Keywords: Arthritis, Infectious, Autoinflammatory diseases, genetics, immunology, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2124–2158) Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: This study describes the characteristic clinical and radiological findings and outcomes of patients with Blau syndrome from a single tertiary care hospital.

Methods: A retrospective chart review of patients with Blau syndrome with NOD2 mutation was conducted to describe key clinical and imaging findings.Children diagnosed with Blau syndrome and followed in the Pediatrics Rheumatology clinic, Department of Pediatrics, XXX, from January 2022 to July 2024, were enrolled for this retrospective chart review. The inclusion criteria included children with clinical features consistent with Blau syndrome (boggy synovial swelling and dermatitis ± ocular features such as uveitis) and pathogenic or likely pathogenic variants in the NOD 2 gene. The molecular analysis was done on the peripheral blood sample drawn after obtaining written consent. Mutational hotspot, exon 4 of the NOD2 gene, was amplified using previously reported primers and Bi-directional Sanger sequencing was carried out. The variants were classified according to the American College of Medical Genetics and Genomics guidelines. The variant calling was performed using the Franklin platform (https://franklin.genoox.com, accessed 8 May 2024).

Results: The diagnosis of Blau syndrome in all nine patients (8 children and one adult) was confirmed genetically. The mean (range) age of children at diagnosis was 60 months (24-108 months). The mean (SD) age of symptom onset was 13 (7.7) months, with an age range of 3 to 24 months. The classic triad of uveitis, arthritis and dermatitis was present in 75% of children. The other manifestations include fever (n=4), cervical lymphadenopathy (n=1), hepatosplenomegaly (n=3) and dysmorphism (n=2). The ultrasound of joints showed synovial proliferation, giving a rounded or globular contour similar to the “sac of marbles”. The most common debilitating morbidity noted was visual impairment. We propose a clinical criterion to facilitate early diagnosis of Blau syndrome in resource-limited settings. Table 1 summarises the key clinical features of our study subjects.The skin lesions include dull-red micropapular eruption on face and extremities and icthyosiform scaling on bilateral legs (Fig 1E,F,I & J).On US imaging, the wrist was the most affected joint (7/8), followed by the knee (6/8). Synovial thickening with a characteristic echogenic appearance was a universal observation in all subjects (Figure 2). A distinct nodular/ finger-like projection of synovium was noted in all cases.

Conclusion: Based on our findings and existing literature, we propose clinical criteria to facilitate early diagnosis of Blau syndrome in such settings. Arthritis with boggy synovial swelling plus two of the following · Skin lesions: flat-topped red-skin coloured micropapules · Uveitis: Anterior uveitis with superficial nummular corneal opacity or Panuveitis with focal chorioretinal atrophy patches in mid-periphery/periphery or granulomatous uveitis· Fever And either of two: · Biopsy (Synovial/ Skin) suggestive of granulomatous inflammation· USG joints: exuberant nodular echogenic synovial proliferation out of proportion to joint effusion

Supporting image 1Figure 1: Representative Features of Blau Syndrome in Case 4 – Ocular features: Posterior synechiae and festooning of pupil (A&B;) Focal patches of chorioretinal atrophy in the mid-periphery, periphery (black arrow, C & D) and peripheral vasculitis (blue arrow, C & D). Dermatological features: Scaly ichthyotic patches on bilateral legs and hands(E&F). Features seen in Case 7: Superficial nummular corneal opacities (white arrow, G & H) with no other ocular features. Dermatological features: Flat-topped erythematous micropapules on face and extremities (I & J)

Supporting image 2Ultrasonographic features of Blau syndrome.

A-C. Tenosynovitis in 3 different patients (A-Case 4; B-Case 7;C-Case 8). There is minimal fluid in the tendon (t) sheath, along with significant filiform echogenic synovial thickening (arrows).

D-G. Intra-articular synovitis in 4 patients (D-Case 1;E-Case 2;F-Case 4; G-Case 5).Knee joint US showing finger-like echogenic projection in the suprapatellar bursa (arrows), along with some joint effusion (D). The synovial proliferation was bright echogenic and nodular (E) in some cases and undulated globular in others (F). The nodular lobulated appearance of intra-articluar synovial proliferation (G), akin to ‘sac of marbles’; as seen in H

Supporting image 3Key clinical features in Blau Syndrome in our cohort


Disclosures: N. Bagri: None; N. Shaikh: None; M. jana: None; S. kalsotra: None; K. Rajkumar: None; M. Chowdhury: None; N. Gupta: None; D. Bhadu: None; V. Gupta: None; R. Chawla: None.

To cite this abstract in AMA style:

Bagri N, Shaikh N, jana M, kalsotra S, Rajkumar K, Chowdhury M, Gupta N, Bhadu D, Gupta V, Chawla R. Blau Syndrome: features beyond the classic triad and proposal for clinical criteria [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/blau-syndrome-features-beyond-the-classic-triad-and-proposal-for-clinical-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blau-syndrome-features-beyond-the-classic-triad-and-proposal-for-clinical-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology